References
- JemalASiegelRWardEMurrayTXuJThunMJCancer statistics, 2007CA Cancer J Clin200757436617237035
- ChoongNVokesEExpanding role of the medical oncologist in the management of head and neck cancerCA Cancer J Clin200858325318096865
- SchlessingerJCell signaling by receptor tyrosine kinasesCell200010321122511057895
- MarkHKirschbaumYYThe ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasmsJ Cell Biochem2000775260
- BunnPAJrFranklinWEpidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancerSemin Oncol200229384412422312
- ChenPXieHSekarMCGuptaKWellsAEpidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movementJ Cell Biol19941278478577962064
- EllerbroekSMHalbleibJMBenavidezMPhosphatidylinositol 3-kinase activity in epidermal growth factor- stimulated matrix metalloproteinase-9 production and cell surface associationCancer Res2001611855186111280738
- LorchJHKlessnerJParkJKEpidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cellsJ Biol Chem2004279371913720015205458
- BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med200635456757816467544
- VermorkenJBMesiaRVegaVCetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy – Results of a randomized phase III (Extreme) study [abstract]Proc Am Soc Clin Oncol2007256091
- KiesMSGhebremichaelMSKatzTLHerbstRSYoussoufianHBurtnessBEGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN) [abstract]Proc Am Soc Clin Oncol2007256024
- ChungCHMirakhurBChanECetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactoseN Engl J Med20083581109111718337601
- HittRIrigoyenANuñezJPhase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC) [abstract]Proc Am Soc Clin Oncol2007256012
- GibsonMKKiesMS SKCetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report [abstract]Proc Am Soc Clin Oncol2009276049
- CohenEEKaneMAListMAPhase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckClin Cancer Res2005118418842416322304
- SoulieresDSenzerNNVokesEEHidalgoMAgarwalaSSSiuLLMulticenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neckJ Clin Oncol200422778514701768
- AgulnikMda Cunha SantosGHedleyDPredictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinibJ Clin Oncol2007252184219017538163
- KimESKiesMSGlissonBSFinal results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer [abstract]Proc Am Soc Clin Oncol2007256013
- CohenEEDavisDWKarrisonTGErlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyLancet Oncol20091024725719201650
- LaiSYLuiVWKoppikarPJIntratumoral epidermal growth factor receptor (EGFR) antisense (AS) DNA in recurrent squamous cell carcinoma of the head and neck (SCCHN): A phase I trial [abstract]Proc Am Soc Clin Oncol2007256009
- DamianoVCaputoRBiancoRNovel toll-likereceptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitorsClin Cancer Res20061257758316428503